Latest:
A Breakthrough for the “Lab Brat”
Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.
Authors
Amanda Blackmon, DO
Latest:
Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML
The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.
Bijal Shah, MD, MS
Latest:
Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL
Experts discuss their combined experience with cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and other immunotoxicities post chimeric antigen receptor (CAR) T-cell therapy, whether Moffitt Cancer Center implements a standardized protocol to address and resolve cell therapy–associated immunotoxicities, how interventions are modified across grades of severity, and the use of prophylactic strategies to mitigate treatment-related adverse events as well as the roles of the multidisciplinary team in patient monitoring during the initial 30 days and the longer-term postinfusion period.
Iván Márquez Rodas, MD, PhD
Latest:
Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma
Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.
Anurag Agrawal, MD
Latest:
Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R
Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.
J. Dominic Femino, MD
J. Dominic Femino, MD, is an associate professor of clinical orthopedic surgery at the Keck School of Medicine of USC and the chief of the USC Musculoskeletal Oncology Center.
Latest:
Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Conclusions
In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.
Alvaro Alencar, MD
Alvaro Alencar, MD, a hematologist/oncologist, an associate professor of clinical medicine, and associate chief medical officer in the Division of Hematology at the University of Miami Sylvester Comprehensive Cancer Center.
Latest:
Dr Alencar on the Ongoing Development of NX-5948 in CLL and B-Cell Malignancies
Alvaro Alencar, MD, discusses research needed to clarify the optimal dosing, role, and sequencing of NX-5948 in CLL and other B-cell malignancies.